JP2005529874A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005529874A5 JP2005529874A5 JP2003585696A JP2003585696A JP2005529874A5 JP 2005529874 A5 JP2005529874 A5 JP 2005529874A5 JP 2003585696 A JP2003585696 A JP 2003585696A JP 2003585696 A JP2003585696 A JP 2003585696A JP 2005529874 A5 JP2005529874 A5 JP 2005529874A5
- Authority
- JP
- Japan
- Prior art keywords
- dry powder
- pharmaceutical composition
- powder pharmaceutical
- composition according
- carbohydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 150000001720 carbohydrates Chemical class 0.000 claims 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229960004017 salmeterol Drugs 0.000 claims 4
- 229960000289 fluticasone propionate Drugs 0.000 claims 3
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- WOTQVEKSRLZRSX-HYSGBLIFSA-N [(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1O[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 WOTQVEKSRLZRSX-HYSGBLIFSA-N 0.000 claims 2
- WOTQVEKSRLZRSX-UHFFFAOYSA-N beta-D-cellobioside octaacetate Natural products CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1 WOTQVEKSRLZRSX-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- ZIJKGAXBCRWEOL-SAXBRCJISA-N Sucrose octaacetate Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 ZIJKGAXBCRWEOL-SAXBRCJISA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 239000001083 [(2R,3R,4S,5R)-1,2,4,5-tetraacetyloxy-6-oxohexan-3-yl] acetate Substances 0.000 claims 1
- 239000001344 [(2S,3S,4R,5R)-4-acetyloxy-2,5-bis(acetyloxymethyl)-2-[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxolan-3-yl] acetate Substances 0.000 claims 1
- NJVBTKVPPOFGAT-BRSBDYLESA-N [(2r,3r,4r,5r)-2,3,4,5,6-pentaacetyloxyhexyl] acetate Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H](OC(C)=O)COC(C)=O NJVBTKVPPOFGAT-BRSBDYLESA-N 0.000 claims 1
- UAOKXEHOENRFMP-ZJIFWQFVSA-N [(2r,3r,4s,5r)-2,3,4,5-tetraacetyloxy-6-oxohexyl] acetate Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)C=O UAOKXEHOENRFMP-ZJIFWQFVSA-N 0.000 claims 1
- WOTQVEKSRLZRSX-JRFIZLOQSA-N [(2r,3r,4s,5r,6r)-4,5,6-triacetyloxy-3-[(2s,3r,4s,5s,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate Chemical group CC(=O)OC[C@H]1O[C@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1O[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)O1 WOTQVEKSRLZRSX-JRFIZLOQSA-N 0.000 claims 1
- HWDSLHMSWAHPBA-UHFFFAOYSA-N [3,4,5-triacetyloxy-6-[3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(COC(=O)C)OC1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1 HWDSLHMSWAHPBA-UHFFFAOYSA-N 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 150000002430 hydrocarbons Chemical group 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000002664 inhalation therapy Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229940013883 sucrose octaacetate Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000004804 winding Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0208609.8A GB0208609D0 (en) | 2002-04-13 | 2002-04-13 | Compositions |
| PCT/GB2003/001595 WO2003088944A1 (en) | 2002-04-13 | 2003-04-10 | Dry powder inhalant composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005529874A JP2005529874A (ja) | 2005-10-06 |
| JP2005529874A5 true JP2005529874A5 (https=) | 2006-06-01 |
Family
ID=9934856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003585696A Pending JP2005529874A (ja) | 2002-04-13 | 2003-04-10 | 乾燥粉末組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20050232998A1 (https=) |
| EP (1) | EP1509199A1 (https=) |
| JP (1) | JP2005529874A (https=) |
| KR (1) | KR20040097348A (https=) |
| CN (1) | CN100362986C (https=) |
| AR (1) | AR039408A1 (https=) |
| AU (1) | AU2003224278A1 (https=) |
| BR (1) | BR0309115A (https=) |
| CA (1) | CA2482249A1 (https=) |
| GB (1) | GB0208609D0 (https=) |
| IL (1) | IL164421A0 (https=) |
| IS (1) | IS7501A (https=) |
| MX (1) | MXPA04010082A (https=) |
| NO (1) | NO20044496L (https=) |
| PL (1) | PL373293A1 (https=) |
| RU (1) | RU2004130438A (https=) |
| TW (1) | TW200407174A (https=) |
| WO (1) | WO2003088944A1 (https=) |
| ZA (1) | ZA200408247B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8337816B2 (en) | 2001-09-17 | 2012-12-25 | Glaxo Group Limited | Dry powder medicament formulations |
| EP1643974A1 (en) * | 2003-07-11 | 2006-04-12 | Glaxo Group Limited | Inhalable pharmaceutical formulations comprising a sugar ester |
| MX2007009656A (es) | 2005-02-10 | 2007-11-07 | Glaxo Group Ltd | Proceso para elaborar lactosa utilizando tecnicas de clasificacion previa y formulaciones farmaceuticas formadas de la misma. |
| GB0605723D0 (en) | 2006-03-23 | 2006-05-03 | 3M Innovative Properties Co | Powder filling processes |
| GB0714134D0 (en) * | 2007-07-19 | 2007-08-29 | Norton Healthcare Ltd | Dry-powder medicament |
| BRPI0816278A2 (pt) * | 2007-09-05 | 2015-09-22 | Pfizer Ltd | forma sal |
| TR201007250A2 (tr) * | 2010-09-01 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Selobioz içeren formülasyon. |
| TR201007251A2 (tr) * | 2010-09-01 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Kalsiyum kanal blokörü formülasyonu. |
| JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| GB201113662D0 (en) | 2011-08-08 | 2011-09-21 | Prosonix Ltd | Pharmaceutical compositions |
| NZ629438A (en) * | 2012-02-28 | 2016-10-28 | Iceutica Holdings Inc | Inhalable pharmaceutical compositions |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| EP2847207B1 (en) | 2012-05-08 | 2019-03-27 | Nicox Ophthalmics, Inc. | Fluticasone propionate nanocrystals |
| EP2874928B1 (en) | 2012-07-19 | 2016-06-15 | Adamis Pharmaceuticals Corporation | Powder feeding apparatus |
| US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| AU2014261538A1 (en) * | 2013-04-29 | 2015-12-10 | Sanofi Sa | Inhalable pharmaceutical compositions and the inhaler devices containing them |
| CN104644618A (zh) * | 2013-11-19 | 2015-05-27 | 上海医药工业研究院 | 一种干粉吸入剂及其制备方法 |
| EP4218734A1 (en) * | 2014-07-31 | 2023-08-02 | Vectura Inc. | Dry powder formulations for inhalation |
| WO2016052897A1 (en) * | 2014-09-30 | 2016-04-07 | Hanmi Pharm. Co., Ltd. | Dry powder for inhalation formulation having improved stability of combined active ingredients |
| KR20160117069A (ko) * | 2015-03-31 | 2016-10-10 | 한미약품 주식회사 | 복합 활성성분의 안정성이 개선된 흡입용 캡슐제 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR8007911A (pt) * | 1979-12-06 | 1981-06-16 | Glaxo Group Ltd | Inalador aperfeicoado |
| SE448277B (sv) * | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| AU591152B2 (en) * | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
| US5202309A (en) * | 1989-06-30 | 1993-04-13 | Merck & Co., Inc. | Antibiotic cyclopeptide fermentation product |
| IL95590A (en) * | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
| GB9004781D0 (en) * | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| PT994887E (pt) * | 1997-07-03 | 2003-04-30 | Elan Drug Delivery Ltd | Glicosidos modificados composicoes que compreendem os mesmos e metodos para a sua utilizacao |
| US6352722B1 (en) * | 1997-12-23 | 2002-03-05 | Quadrant Holdings Cambridge Limited | Derivatized carbohydrates, compositions comprised thereof and methods of use thereof |
| GB9916316D0 (en) * | 1999-07-12 | 1999-09-15 | Quadrant Holdings Cambridge | Dry powder compositions |
| UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| GB0020616D0 (en) * | 2000-08-21 | 2000-10-11 | Quadrant Holdings Cambridge | Particulates |
| JP2004526674A (ja) * | 2000-12-01 | 2004-09-02 | バテル・メモリアル・インスティテュート | 液体処方物中における生体分子の安定化のための方法 |
| PT1372608E (pt) * | 2001-03-30 | 2008-01-04 | Jagotec Ag | Formulações de aerossol médicas |
| WO2003099764A1 (en) * | 2002-05-28 | 2003-12-04 | Theravance, Inc. | ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS |
-
2002
- 2002-04-13 GB GBGB0208609.8A patent/GB0208609D0/en not_active Ceased
-
2003
- 2003-04-10 CA CA002482249A patent/CA2482249A1/en not_active Abandoned
- 2003-04-10 US US10/510,968 patent/US20050232998A1/en not_active Abandoned
- 2003-04-10 JP JP2003585696A patent/JP2005529874A/ja active Pending
- 2003-04-10 AU AU2003224278A patent/AU2003224278A1/en not_active Abandoned
- 2003-04-10 WO PCT/GB2003/001595 patent/WO2003088944A1/en not_active Ceased
- 2003-04-10 KR KR10-2004-7016301A patent/KR20040097348A/ko not_active Withdrawn
- 2003-04-10 RU RU2004130438/15A patent/RU2004130438A/ru not_active Application Discontinuation
- 2003-04-10 CN CNB038134608A patent/CN100362986C/zh not_active Expired - Fee Related
- 2003-04-10 PL PL03373293A patent/PL373293A1/xx unknown
- 2003-04-10 EP EP03720702A patent/EP1509199A1/en not_active Withdrawn
- 2003-04-10 BR BR0309115-5A patent/BR0309115A/pt not_active IP Right Cessation
- 2003-04-10 MX MXPA04010082A patent/MXPA04010082A/es unknown
- 2003-04-11 AR ARP030101279A patent/AR039408A1/es not_active Application Discontinuation
- 2003-04-11 TW TW092108404A patent/TW200407174A/zh unknown
-
2004
- 2004-10-05 IL IL16442104A patent/IL164421A0/xx unknown
- 2004-10-11 IS IS7501A patent/IS7501A/is unknown
- 2004-10-12 ZA ZA200408247A patent/ZA200408247B/xx unknown
- 2004-10-21 NO NO20044496A patent/NO20044496L/no not_active Application Discontinuation
-
2007
- 2007-11-05 US US11/934,983 patent/US20080060645A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005529874A5 (https=) | ||
| EP2490670B1 (en) | Composition for inhalation | |
| EP2429497B1 (en) | Process for preparing microparticles | |
| RU2004130438A (ru) | Сухая порошковая композиция для ингаляции | |
| CN101756942B (zh) | 一种经口腔用肺吸入粉雾剂 | |
| RU2002116251A (ru) | Аэрозольная композиция, содержащая формотерол | |
| SA99200718B1 (ar) | عامل فعال activ agent في صورة مسحوق جاف dry powder للاعطاء في الرئة lung | |
| ES2613754T3 (es) | Uso de glicopirrolato para tratar la taquicardia | |
| EP2528600B1 (en) | Dry powder pharmaceutical composition comprising tiotropium and fluticasone | |
| JP2005530733A5 (https=) | ||
| KR20040099436A (ko) | 건조 분말 조성물 | |
| US20050152847A1 (en) | Novel formulation | |
| EP2533765A2 (en) | Pharmaceutical compositions comprising formoterol and mometasone | |
| ES2705494T3 (es) | Productos farmacológicos para la inhalación de polvo seco que presentan propiedades de control de la humedad y procedimientos de administración de los mismos | |
| WO2011093811A2 (en) | Pharmaceutical preparations comprising formoterol and fluticasone | |
| US20230041980A1 (en) | Method of protecting a respiratory tract or a lung from damage, method of protecting a lung from pressure damage induced by a ventilator, method of suppressing spread of infection with viruses or bacteria that cause pneumonia in pulmonary bronchial epithelial cells or alveolar epithelial cells, and nasal spray | |
| JPWO2012147705A1 (ja) | トレハロースを含有する炎症性呼吸器疾患の治療剤 | |
| WO2011093814A2 (en) | A pharmaceutical combination comprising formoterol and ciclesonide | |
| Arora et al. | Liposome: a novel aerosol carrier of doxophylline in treatment of chronic asthma & chronic obstructive pulmonary disease | |
| Kee et al. | Unlocking the Potential of Nanotechnology in Advancing Pulmonary Drug Delivery Systems | |
| WO2011093810A2 (en) | Dry powder pharmaceutical composition comprising tiotropium and mometasone |